# Veterinary Drug Compounding Regulations: What Clinicians Must Know


## Key Takeaways

- Veterinary drug compounding is legally permissible only when an approved, commercially available product cannot meet a specific patient's medical need, and must be performed within a valid veterinarian-client-patient relationship.
- The US Food and Drug Administration's Center for Veterinary Medicine (FDA CVM) is the primary regulatory authority, overseeing compounding policy and distinguishing it from drug manufacturing, which involves large-scale production and FDA approval.
- Compounding from bulk drug substances is restricted; preference is given to using approved human or animal drug products as starting materials, with specific limitations on eligible bulk substances.
- Compounded preparations for food-producing animals necessitate rigorous residue avoidance protocols and the veterinarian's determination of appropriate withdrawal periods, informed by the drug's pharmacology and formulation.
- Clinicians must meticulously document the rationale for compounding, including the failure to find a suitable approved product, the specific patient need, the pharmacy used, and the assigned beyond-use date and withdrawal interval for food animals.
- Close monitoring for clinical response, adverse reactions, and physical stability is critical for compounded preparations due to potential variability in batch consistency, bioavailability, and potency compared to approved drugs.

---

Compounding is the preparation of a drug product to meet a patient's specific medical need when an approved, commercially available product cannot be used. In veterinary medicine, compounding occupies a regulatory space distinct from both approved drug manufacturing and extralabel drug use. This article explains the legal framework that governs veterinary compounding, the conditions under which compounding is permissible, and the clinical obligations that attach to prescribing compounded preparations. It is written for practicing veterinarians who must decide when compounding is lawful, how to select a compliant compounding pharmacy, and how to document and monitor therapy.

The regulatory environment for veterinary compounding is shaped primarily by the US Food and Drug Administration (FDA) and its Center for Veterinary Medicine (CVM), which oversees approved animal drugs, labeling requirements, extralabel use policy, and compounding guidance. The [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary) portal serves as the primary reference for current regulatory positions. Professional organizations such as the American Veterinary Medical Association (AVMA) provide complementary practice guidance, including [AVMA practice resources](https://www.avma.org/resources-tools) relevant to pharmacy and prescribing decisions. This article addresses the legal and clinical framework as it stands in the United States, with attention to how requirements differ across production animal systems and regions.

## At a Glance

| Parameter | What Clinicians Must Know |
|---|---|
| Legal basis | Compounding is lawful only when an approved drug cannot be used to meet a patient's medical need |
| Primary regulator | FDA Center for Veterinary Medicine oversees animal drug approval and compounding policy |
| Bulk drug substances | Compounding from bulk ingredients is restricted, use of approved human or animal drug products as starting materials is generally preferred |
| Patient requirement | A valid veterinarian-client-patient relationship must exist before compounding is considered |
| Labeling | Compounded preparations must be labeled with species, patient identification, ingredients, concentration, and beyond-use date |
| Record keeping | Prescriptions, formulations, and quality assurance documentation must be retained and available for inspection |
| Food animals | Compounding for food-producing species carries additional residue avoidance obligations and withdrawal period determinations |
| Professional guidance | AVMA and other professional bodies publish stewardship and compliance resources that supplement FDA requirements |

## The Regulatory Distinction Between Compounding and Manufacturing

Compounding is not manufacturing. The FDA distinguishes compounding, which is the preparation of a drug for an identified patient based on a prescription, from manufacturing, which is the large-scale production of drugs for general distribution. The distinction matters because manufacturers must obtain FDA approval demonstrating safety, efficacy, and quality before marketing a drug. Compounders are not required to obtain such approval, but they operate under a narrower set of permitted activities.

The [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary) resource describes the agency's position that compounding is intended to address the needs of individual animals when an approved drug is not available or is not clinically appropriate. When a commercially available approved product exists that would meet the patient's needs, compounding that product or a copy of it is not permitted. This restriction prevents compounding from functioning as an unapproved alternative to the drug approval process.

## The Legal Foundation: Food, Drug, and Cosmetic Act Provisions

The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the statutory basis for FDA oversight of animal drugs. Section 512 of the Act governs the approval of new animal drugs and prohibits the introduction of unapproved drugs into interstate commerce. Compounded preparations are technically unapproved drugs, but FDA exercises enforcement discretion under specified conditions.

Two sections of the FD&C Act are particularly relevant to veterinary compounding. Section 503A, added by the FDA Modernization Act of 1997, addresses compounding by licensed pharmacists and physicians for human patients. Section 503B, added by the Drug Quality and Security Act of 2013, establishes outsourcing facilities that may compound larger quantities without individual prescriptions. Neither section directly addresses veterinary compounding, which is why FDA has issued separate guidance documents specific to animal drug compounding.

The [AVMA practice resources](https://www.avma.org/resources-tools) page directs veterinarians to the relevant FDA guidance documents and summarizes the professional obligations that accompany compounding decisions. The AVMA emphasizes that compounding must be based on a valid veterinarian-client-patient relationship, must use approved drugs as starting materials whenever possible, and must be documented thoroughly.

## Conditions for Lawful Veterinary Compounding

FDA has articulated conditions under which it will not ordinarily take enforcement action for veterinary compounding. These conditions appear in the agency's guidance documents and are summarized in the [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary) resource. The core requirements are as follows.

First, compounding must be performed by or on the order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship. The veterinarian must have examined the animal or made medically appropriate and timely visits to the premises where the animal is kept.

Second, the compounded drug must be intended for an individual animal or a small group of animals with a specific medical need. Compounding for inventory or for anticipated future needs is not permitted.

Third, the compounded preparation must be necessary because an approved drug cannot be used. This necessity may arise because no approved drug exists for the indication, the approved drug is not commercially available, or the approved drug cannot be used due to an adverse reaction, contraindication, or other clinical limitation.

Fourth, the compounding must be performed by a licensed pharmacist or veterinarian using approved drug products as starting materials. Compounding from bulk drug substances is permitted only when no approved product can be used as a starting material, and even then, only certain bulk substances are eligible.

## Food-Producing Animals and Residue Avoidance

Compounding for food-producing species introduces additional obligations. The [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary) resource notes that compounded preparations used in food animals must not result in illegal drug residues in edible tissues or milk. The veterinarian must establish an appropriate withdrawal period, which requires knowledge of the pharmacological properties of the active ingredient and the formulation.

The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address the international framework for veterinary drug use in food animals, including residue monitoring and trade implications. Veterinarians working with food animals should be aware that compounding decisions may affect export certification and international trade compliance.

## Antimicrobial Stewardship and Compounding

Compounding of antimicrobial drugs raises specific stewardship concerns. The [AVMA antimicrobial use and stewardship guidance](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasizes that compounded antimicrobials should be used only when no approved product is appropriate and when the compounding does not undermine judicious use principles. Compounding an antimicrobial to create a fixed-dose combination or to extend a supply beyond the approved product's availability may encourage use patterns that promote resistance.

The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides pharmacology reference material that supports clinical decision-making about drug selection, including situations where compounding may be clinically justified. Veterinarians should consult current formulary references when selecting compounded preparations, particularly for species where pharmacokinetic data are limited.

## The Clinical Assessment: When Compounding Is the Right Choice

The decision to compound begins with a drug availability problem, not a convenience preference. Work through a defined sequence before writing a prescription. First, confirm that no approved product exists in the strength, dosage form, or combination needed for the target species. Second, verify that the approved product cannot be adapted through legal extralabel use, such as splitting tablets or adjusting dose intervals. Third, determine whether the patient's status, for example dysphagia, refractory behavior, or a metabolic limitation, makes the approved product clinically unusable. Fourth, document the reasoning in the medical record before the compound is dispensed.

The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) publishes the current policy framework that distinguishes lawful compounding from unapproved manufacturing. A clinician who compounds in response to a patient-specific need, with a valid veterinarian-client-patient relationship, and without a commercially available alternative is operating within the intended scope. A clinician who compounds in anticipation of general demand, or who produces large batches for inventory, has crossed into manufacturing territory regardless of intent.

Patient status changes the calculus. A dog with a stable chronic condition may tolerate a commercially available tablet split into quarters, whereas a cat with pica or a fractious temperament may require a flavoured liquid that no manufacturer produces. A food-producing animal presents a different constraint set entirely. Residue avoidance, withdrawal interval estimation, and the prohibition on certain drugs in specific production classes take priority over formulation elegance. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacology context that should inform whether a compounded alternative is pharmacokinetically rational before the regulatory question is even considered.

## Decision Points That Change the Outcome

Three clinical scenarios illustrate where the correct choice diverges.

**Scenario one: Companion animal, chronic disease.** A small-breed dog requires a drug available only as a human tablet in a strength that forces awkward splitting. Compounding to a patient-specific oral suspension is defensible if stability data exist and the prescriber accepts responsibility for bioavailability assumptions. The decision changes if a veterinary-approved product with a flexible dosing schedule exists, because the approved product carries labelled safety and efficacy data that no compound can match.

**Scenario two: Food animal, acute disease.** A swine producer needs a water-soluble antimicrobial for a group treatment. The regulatory analysis changes fundamentally because withdrawal periods for compounded preparations must be estimated, not read from a label. The [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) address residue control and food safety expectations that inform how conservative the withdrawal estimate must be. When an approved product exists for the indication, using it is also safer, it is the only choice that carries a legal residue tolerance.

**Scenario three: Exotic or minor species.** A avian patient needs a drug approved only for dogs and cats. Compounding is often the only practical route, but the prescriber must recognize that no pharmacokinetic data exist for the species. The dose must be extrapolated from related species, and the margin of safety is unknown. This is where the evidence base is genuinely limited, and the record should reflect that uncertainty.

## Monitoring Parameters and What Each One Detects

Compounded preparations require closer monitoring than approved products because batch consistency, stability, and bioavailability are less certain. Establish a monitoring plan at the time of prescribing, not after an adverse event.

| Monitoring Parameter | What It Detects | Action Threshold | Documentation Requirement |
|---|---|---|---|
| Clinical response at expected interval | Bioavailability failure or incorrect potency | No response within the expected therapeutic window | Record response assessment and any dose adjustment |
| Adverse reaction profile | Excipient intolerance, contamination, or concentration error | Any unexpected reaction, especially gastrointestinal signs | Report to the FDA Adverse Event Reporting system and the compounding pharmacy |
| Serum drug concentration where available | Absorption variability between batches | Concentration outside the therapeutic range for the species | Record concentration, batch number, and pharmacy |
| Residue screening in food animals | Withdrawal interval miscalculation | Any detectable residue above tolerance | Document the screening method and result in the treatment record |
| Physical stability of the preparation | Degradation, precipitation, or microbial growth | Visible change before the beyond-use date | Notify the pharmacy and discontinue use |

The monitoring plan must be species-appropriate. A food animal requires residue-focused monitoring, while a companion animal requires response and tolerability monitoring. The [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasize that compounded antimicrobials deserve particular scrutiny because subpotent preparations can drive resistance selection.

## Documentation and the Compliance Record

The medical record is the primary defense in any regulatory review. For every compounded prescription, document the following: the approved product search that failed, the clinical justification for compounding, the pharmacy used, the batch number if available, the beyond-use date, the withdrawal interval assigned for food animals, and the monitoring plan. Include the client communication about the differences between a compounded preparation and an approved product, particularly regarding potency assurance and adverse event reporting.

A compliance checklist should be reviewed at each compounding decision:

- Confirm a valid veterinarian-client-patient relationship exists.
- Confirm no approved product meets the clinical need.
- Confirm the compound is intended for a specific patient, not inventory.
- Confirm the pharmacy is licensed and, where applicable, registered for veterinary compounding.
- Confirm the drug is not prohibited for the species or production class.
- Assign a withdrawal interval for food animals based on the most conservative estimate.
- Document the clinical rationale and client communication.
- Establish a monitoring plan with specific parameters.
- Report any adverse event to the appropriate authority.

## Resources for Further Information

The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) maintains the current compounding policy documents, including the memorandum of understanding governing pharmacy inspections and the list of drugs prohibited from compounding. The [American Veterinary Medical Association practice resources](https://www.avma.org/resources-tools) include policy statements on compounding and links to state veterinary board requirements. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides pharmacological background for evaluating whether a compounded formulation is clinically rational. For food animal practice, the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) and the [AVMA antimicrobial stewardship guidance](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) frame the residue and resistance considerations that must accompany any compounded antimicrobial use.

State veterinary boards and the pharmacy boards in each jurisdiction publish their own compounding rules, and these vary. A practitioner serving patients in multiple states must check the requirements in each state where the practice operates. The federal framework sets the floor, but state law can impose additional restrictions on which drugs may be compounded, which pharmacies may compound them, and what records must be kept.

## Recognized Complications and Early Detection

Compounded preparations fail in predictable patterns. The most consequential failure is microbial contamination, which arises from nonsterile ingredients, inadequate environmental controls, or improper storage after dispensing. Early detection depends on visual inspection for turbidity, particulate matter, or color change, but many contaminants produce no visible alteration. Clinicians should question any preparation that arrives without documentation of sterility testing, particularly when intended for ophthalmic, intrathecal, or intravenous use.

Potency errors constitute a second major failure mode. A preparation labelled at one concentration may contain substantially more or less active drug because of calculation error, measurement imprecision, or use of a different salt form than specified. Clinical detection is indirect: unexpected efficacy, unexpected toxicity, or a therapeutic response that does not match the dose administered. When a patient deteriorates after a change from an approved product to a compounded version, potency error should rank high on the differential list.

Stability failures manifest as precipitation, color shift, or loss of potency before the labelled beyond-use date. These are insidious because the preparation may appear normal while delivering subtherapeutic drug concentrations. The discriminating check is to compare the physical appearance against the compounding pharmacy's stability monograph and to confirm that the beyond-use date was assigned according to published stability data instead of a default interval.

Adverse reactions to excipients represent a fourth category. Compounded products may contain preservatives, solvents, or flavourings that differ from the approved product, and these can trigger hypersensitivity or local tissue reactions. Detection requires a temporal association between administration and the reaction, followed by review of the compounding record for ingredient changes.

| Observation | Likely Cause | Discriminating Check |
|---|---|---|
| No therapeutic response at expected dose | Potency error or stability failure | Request assay documentation, compare batch records |
| Toxicity at labelled dose | Concentration error or salt-form mismatch | Verify calculation against original prescription |
| Turbidity or precipitate | Incompatibility or microbial growth | Culture and physical stability assessment |
| Injection-site reaction | Excipient sensitivity | Review ingredient list against approved product |
| Clinical deterioration after product switch | Subpotent preparation | Rechallenge with approved product if feasible |

## Common Errors in Clinical Use

Less experienced clinicians frequently treat compounded products as bioequivalent to approved drugs. This assumption fails because pharmacokinetics can differ with the salt form, vehicle, and route. The corrective action is to treat each compounded preparation as a distinct product and to monitor response more closely than would be necessary for an approved drug.

A second recurring error is prescribing a compounded antimicrobial when an approved product would serve, often to circumvent palatability problems or dosing frequency. This practice undermines stewardship because compounded products lack the quality assurance of approved drugs and may deliver subtherapeutic concentrations that select for resistance. The corrective action is to exhaust approved options first and to document the clinical justification when compounding is chosen. Professional guidance on judicious antimicrobial use supports this hierarchy [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance).

A third error involves food-producing animals. Clinicians sometimes assume that compounding from an approved drug for that species preserves the label withdrawal interval. It does not. The compounded preparation has no established withdrawal period, and residue risk depends on the active ingredient, the formulation, and the route. The corrective action is to consult current regulatory guidance and, where uncertainty persists, to use a conservative withdrawal interval or to avoid compounding altogether in animals destined for the food chain. International standards for veterinary drug residues in food-producing animals are set through the [WOAH terrestrial animal health code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/), and clinicians should align residue decisions with those frameworks.

## Limitations of the Evidence Base

The evidence supporting compounded drug use in veterinary patients is thin. Most compounded preparations have no pharmacokinetic, safety, or efficacy data in the target species. Published clinical experience is largely anecdotal, and extrapolation from human data or from other species carries real risk. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides species-specific pharmacology that can help clinicians judge whether a compounded formulation is plausible, but it cannot substitute for product-specific data that do not exist.

Expert opinion still differs on several points. Some specialists accept compounding when no approved product exists in the needed dosage form, while others require evidence of clinical necessity beyond convenience. There is also disagreement about whether pharmacies should be required to provide potency and sterility certificates for every batch, and about the acceptable margin of error for compounded products. These disagreements reflect the absence of standardized quality benchmarks, and clinicians should be aware that a pharmacy's voluntary certifications do not guarantee regulatory oversight.

## Escalation and Referral

Referral to a specialist is warranted when a compounded preparation fails to produce the expected response and the underlying disease is progressive. A veterinary pharmacologist or internal medicine specialist can help distinguish product failure from disease progression and can recommend alternative therapeutic strategies.

Laboratory involvement becomes necessary when contamination is suspected. Microbiology culture of the preparation itself, also the patient, can confirm the source of infection. Analytical chemistry services can verify potency when clinical response does not match expectations, though such testing is not always readily available.

Regulatory reporting is appropriate when a preparation causes an adverse reaction or when a pharmacy ships a product that is visibly defective. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) accepts adverse event reports for animal drugs, including compounded products, and these reports contribute to the agency's ability to identify problematic pharmacies and formulations. Clinicians should also report pharmacies that compound without a valid prescription or that market products for uses that clearly exceed lawful compounding boundaries.

State veterinary boards and pharmacy boards have overlapping jurisdiction over compounding, and a complaint to one may not reach the other. When a pattern of defective products emerges, reporting to both bodies increases the chance of corrective action.

## Frequently Asked Questions

### How Do I Justify the Cost of a Compounded Product to a Client When an Approved Product Exists?

Explain the clinical rationale first, then the economics. When an approved product is available, compounding should address a documented medical need, such as dose flexibility, palatability, or an adverse reaction to a preservative. Cost alone is not a lawful justification under FDA policy. If the approved product is clinically unsuitable, document that reasoning in the medical record and obtain informed consent that states the compounded product is not FDA-approved and has not undergone the same safety, efficacy, and quality testing. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) publishes current compounding guidance that defines acceptable justifications, and the [AVMA practice resources](https://www.avma.org/resources-tools) offer client communication templates that frame the discussion around medical need instead of price.

### What Are My Options When a Compounding Pharmacy Cannot Verify Stability or Compatibility?

Treat the pharmacy's inability as a red flag, not a minor inconvenience. A reputable pharmacy should provide stability data, a beyond-use date with a stated basis, and compatibility information for the specific formulation. If that information is unavailable, request a different dosage form, a different strength of the same drug, or a commercially available alternative. For critical medications, consult the [MSD Veterinary Manual](https://www.msdvetmanual.com/) for pharmacology guidance on the drug class and consider whether the clinical risk of an unverified formulation exceeds the risk of switching therapy. Document the pharmacy's response and your alternative search in the record. If no verified option exists, inform the client that the product carries unknown stability risk and schedule earlier follow-up to assess therapeutic effect and adverse effects.

### How Does the Regulatory Picture Change When I Compound for a Non-Traditional Species?

The legal framework does not change with species, but the risk assessment does. For food-producing animals, residue avoidance and withdrawal intervals become the dominant concern, and the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) inform international expectations for food safety and trade. For non-food species such as reptiles, birds, or exotic mammals, the absence of approved products is common, but the same conditions apply: no approved product exists, the compounded product is intended for an individual patient, and the prescription is written by a veterinarian within a valid veterinarian-client-patient relationship. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) distinguishes between compounding for food animals and non-food animals, and the documentation burden is heavier when residues could enter the human food supply.

### What Should I Record in the Medical Record Beyond the Prescription Itself?

Record the clinical justification for compounding, including why no approved product was suitable. Note the active ingredient, strength, dosage form, route, prescribed dose, and the pharmacy or in-house preparation location. Document the client's informed consent, including disclosure that the product is not FDA-approved. For food-producing animals, record the withdrawal interval and the basis for that interval. Include the batch or lot number, the beyond-use date, and any stability information provided by the pharmacy. The [AVMA practice resources](https://www.avma.org/resources-tools) provide documentation checklists that align with professional standards. If you prepare the product in-house, record the compounding procedure, the personnel involved, and the quality checks performed. This record must support your decision if the prescription is later reviewed by a state board or FDA inspector.

### How Do I Explain Compounding Risks to a Client Without Undermining Their Confidence in Treatment?

Frame the conversation around informed consent instead of apology. State that the product is prepared specifically for their animal because the approved product was not suitable, and that compounded drugs do not carry the same FDA review as approved drugs. Explain the specific risk that matters for their case, such as unknown stability, variable absorption, or residue risk in a food animal. The [AVMA antimicrobial stewardship resources](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance) emphasize that clients understand risk when it is tied to a concrete outcome. Give them a monitoring plan, such as observing for reduced effect or adverse signs, and a clear point of contact if concerns arise. This approach preserves trust by demonstrating that you have assessed the risk and have a plan to detect failure.

### When Is It Acceptable to Prepare a Compounded Product In-House instead of Through an External Pharmacy?

In-house preparation is acceptable when the product is simple, the equipment and technique are adequate, and the volume is appropriate for a single patient. A sterile ophthalmic solution prepared in a practice without a laminar flow hood is not acceptable, whereas a flavoured oral suspension from a crushed tablet may be. The [FDA Center for Veterinary Medicine](https://www.fda.gov/animal-veterinary) guidance distinguishes between pharmacy compounding and manufacturing, and the distinction often turns on scale and equipment. If your practice lacks the equipment to verify uniformity, potency, or sterility, refer the prescription to a pharmacy with that capacity. Document the preparation method, the personnel, and the quality checks performed. When in doubt, external compounding is the safer choice because the pharmacy carries liability and quality assurance infrastructure that a general practice does not.

## Related Clinical & Scientific Guides

* [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
* [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary)
* [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive)


## References and Further Reading

- [Food supply and food safety issues in China.](https://pubmed.ncbi.nlm.nih.gov/23746904/). 2013.
- [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM.
- [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.
- [American Veterinary Medical Association Practice Resources](https://www.avma.org/resources-tools). American Veterinary Medical Association.
- [WOAH Terrestrial Animal Health Code](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/). WOAH.

## Related Articles

- [Drug Interactions with Antihypertensive Medications in Veterinary Patients](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antihypertensive-medications-veterinary)
- [Drug Interactions in Veterinary Oncology: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-veterinary-oncology-managing-polypharmacy)
- [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references)
- [Drug Interactions with Antacids and Gastroprotectants in Veterinary Patients](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antacids-veterinary)
- [Drug Interactions in Polypharmacy: A Clinical Decision Framework](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-polypharmacy-clinical-decision-framework)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.